Arcadia Biosciences (NASDAQ:RKDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report published on Saturday. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $6.00 price target on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Trading Down 0.4 %

Arcadia Biosciences stock opened at $2.72 on Friday. Arcadia Biosciences has a 12 month low of $1.85 and a 12 month high of $3.93. The company has a market capitalization of $3.70 million, a price-to-earnings ratio of -0.53 and a beta of 1.34. The business’s fifty day simple moving average is $2.82 and its two-hundred day simple moving average is $2.68.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). The firm had revenue of $1.31 million during the quarter, compared to the consensus estimate of $0.95 million. Arcadia Biosciences had a negative return on equity of 57.51% and a negative net margin of 127.29%. During the same quarter in the previous year, the firm earned ($2.64) EPS. On average, equities research analysts predict that Arcadia Biosciences will post -1.7 EPS for the current year.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.